cmv luciferase firefly 2a rfp puro  (AMS Biotechnology)

Journal: Cancers

Article Title: Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models

doi: 10.3390/cancers15184478

Figure Lengend Snippet: Effects of Temozolomide (TMZ) on glioblastoma cells in 3D tumor spheroid assay. ( A – F ) Dose–response effect of TMZ treatment on U87MG ( A – C ) and U118MG ( D – F ) spheroid size ( A , D ) and cytotoxicity ( B , E ). The spheroid area (red line) and fluorescent-positive surface (blue line) were quantified per spheroid ( C , F ). Representative pictures of cells after 69 h of post-treatment with 0, 100, and 1000 µM of TMZ are shown. Scale = 500 µm. The assay was performed with 3 to 4 replicates from 2 to 3 independent experiments. Data represent the mean and SEM. Statistical differences were determined using a mixed-effects model (REML, groups and time as factor) and Bonferroni’s multiple comparisons test (vs. control, * p ≤ 0.05).

Article Snippet: The U87MG-RFP-Luc cells (transduced with lentiviral biscitronic vector LVP009-PBS from AMSBIO, Abingdon, UK) expressing firefly luciferase (Luc) and red fluorescence protein (RFP) were cultured in RPMI medium as described above, including 8 μg/mL of Puromycin.

Techniques:

Journal: Cancers

Article Title: Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models

doi: 10.3390/cancers15184478

Figure Lengend Snippet: Effects of Temozolomide (TMZ) treatment in glioblastoma mouse subcutaneous graft models. ( A – D ) Impact of TMZ at 10 mg/kg administered 5 times a week (p.o.) on tumor volume in GL261 allograft ( A ), U87MG xenograft ( B ), U118MG xenograft ( C ), and U138MG xenograft ( D ) models. Discontinuous line highlights treatment beginning. Statistical differences between the groups were determined using a mixed-effects model (REML, groups and time as factor) followed by Bonferroni’s multiple comparisons test (* p ≤ 0.05). Data represent mean and SD. n = 10 ( A ), n = 6 ( B ), n = 7 ( C ), and n = 8 ( D ) mice per group at the start of treatments.

Article Snippet: The U87MG-RFP-Luc cells (transduced with lentiviral biscitronic vector LVP009-PBS from AMSBIO, Abingdon, UK) expressing firefly luciferase (Luc) and red fluorescence protein (RFP) were cultured in RPMI medium as described above, including 8 μg/mL of Puromycin.

Techniques:

Journal: Cancers

Article Title: Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models

doi: 10.3390/cancers15184478

Figure Lengend Snippet: Effects of Temozolomide (TMZ) treatment in the U87MG-RFP-Luc glioblastoma mouse orthotopic xenograft model. ( A – C ) Impact of TMZ at 10 mg/kg administered 5 times a week (p.o.) on tumor volume measured by bioluminescence imaging ( A ), body weight ( B ), and survival ( C ). Discontinuous line highlights treatment beginning. Statistical differences between the groups were determined using a mixed-effects model (REML, groups and time as factor) followed by Bonferroni’s multiple comparisons test (* p ≤ 0.05, control vs. all other condition; $ p ≤ 0.05, TMZ 10 mg/kg vs. Sham). Data represent mean and SD. n = 8 mice per group at the start of treatments. For body weight, data reporting was stopped when the first mouse per group had to be sacrificed.

Article Snippet: The U87MG-RFP-Luc cells (transduced with lentiviral biscitronic vector LVP009-PBS from AMSBIO, Abingdon, UK) expressing firefly luciferase (Luc) and red fluorescence protein (RFP) were cultured in RPMI medium as described above, including 8 μg/mL of Puromycin.

Techniques: Imaging

Journal: Cancers

Article Title: Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models

doi: 10.3390/cancers15184478

Figure Lengend Snippet: Effects of Fingolimod on GBM cells in 3D tumor spheroid assay. ( A – F ) Dose–response effect of Fingolimod treatment on U87MG ( A – C ) and GL261 ( D – F ) spheroid size ( A , D ) and cytotoxicity ( B , E ). The spheroid area and fluorescent-positive surface were quantified per spheroid. Representative pictures of cells after 69 h of post-treatment with 0, 5, and 10 µM of Fingolimod are shown. Scale = 500 µm. The assay was performed with 3 to 4 replicates from 2 to 3 independent experiments. Data represent mean and SEM. Statistical differences were determined using a mixed-effects model (REML, groups and time as factor) and Bonferroni’s multiple comparisons test (vs. control, * p ≤ 0.05).

Article Snippet: The U87MG-RFP-Luc cells (transduced with lentiviral biscitronic vector LVP009-PBS from AMSBIO, Abingdon, UK) expressing firefly luciferase (Luc) and red fluorescence protein (RFP) were cultured in RPMI medium as described above, including 8 μg/mL of Puromycin.

Techniques:

Journal: Cancers

Article Title: Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models

doi: 10.3390/cancers15184478

Figure Lengend Snippet: Effects of Temozolomide (TMZ) and Fingolimod treatments in the U87MG human orthotopic xenograft model. ( A – D ) Impact of TMZ at 1 and 10 mg/kg, Fingolimod at 5 mg/kg, or a combination administered 5 times a week (p.o.) on tumor volume measured by bioluminescence imaging, including representative images ( A ), body weight ( B ), neuroscore ( C ), and survival ( D ). Discontinuous line highlights treatment beginning. Statistical differences between the groups were determined using a mixed-effects model (REML, groups and time as factor) followed by Tukey’s multiple comparisons test (* p ≤ 0.05, vs. Control; $ p ≤ 0.05, Fingolimod 5 mg/kg vs. TMZ 1 mg/kg or TMZ 1 mg/kg + Fingolimod 5 mg/kg; & p ≤ 0.05, Fingolimod 5 mg/kg vs. Sham; £ p ≤ 0.05, Fingolimod 5 mg/kg vs. TMZ 1 mg/kg or TMZ 1 mg/kg + Fingolimod 5 mg/kg or TMZ 10 mg/kg or Sham; # p ≤ 0.05, TMZ 10 mg/kg vs. TMZ 1 mg/kg or TMZ 1 mg/kg + Fingolimod 5 mg/kg; ¤ p ≤ 0.05, Control vs. TMZ 10 mg/kg or TMZ 1 mg/kg or TMZ 1 mg/kg or TMZ 1 mg/kg + Fingolimod 5 mg/kg or Sham; § p ≤ 0.05, Fingolimod 5 mg/kg vs. TMZ 10 mg/kg or TMZ 1 mg/kg or TMZ 1 mg/kg or TMZ 1 mg/kg + Fingolimod 5 mg/kg or Sham). Data represent mean and SD. n = 6–8 mice per group at the start of treatments.

Article Snippet: The U87MG-RFP-Luc cells (transduced with lentiviral biscitronic vector LVP009-PBS from AMSBIO, Abingdon, UK) expressing firefly luciferase (Luc) and red fluorescence protein (RFP) were cultured in RPMI medium as described above, including 8 μg/mL of Puromycin.

Techniques: Imaging